178 related articles for article (PubMed ID: 33878504)
1. Validation of the Radiographic Global Impression of Change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH).
Lim R; Shailam R; Hulett R; Skrinar A; Nixon A; Williams A; Nixon M; Thacher TD
Bone; 2021 Jul; 148():115964. PubMed ID: 33878504
[TBL] [Abstract][Full Text] [Related]
2. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score.
Thacher TD; Pettifor JM; Tebben PJ; Creo AL; Skrinar A; Mao M; Chen CY; Chang T; San Martin J; Carpenter TO
Bone; 2019 May; 122():76-81. PubMed ID: 30772600
[TBL] [Abstract][Full Text] [Related]
3. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
4. Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale.
Whyte MP; Fujita KP; Moseley S; Thompson DD; McAlister WH
J Bone Miner Res; 2018 May; 33(5):868-874. PubMed ID: 29297597
[TBL] [Abstract][Full Text] [Related]
5. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
[TBL] [Abstract][Full Text] [Related]
6. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
9. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
10. Monitoring response to conventional treatment in children with XLH: Value of ALP and Rickets Severity Score (RSS) in a real world setting.
Uday S; Shaw NJ; Mughal MZ; Randell T; Högler W; Santos R; Padidela R
Bone; 2021 Oct; 151():116025. PubMed ID: 34052463
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.
Namba N; Kubota T; Muroya K; Tanaka H; Kanematsu M; Kojima M; Orihara S; Kanda H; Seino Y; Ozono K
J Endocr Soc; 2022 May; 6(5):bvac021. PubMed ID: 35356008
[TBL] [Abstract][Full Text] [Related]
12. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
13. Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy.
Brener A; Lebenthal Y; Cleper R; Kapusta L; Zeitlin L
Ther Adv Endocrinol Metab; 2021; 12():20420188211001150. PubMed ID: 33796255
[TBL] [Abstract][Full Text] [Related]
14. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study.
Mindler GT; Stauffer A; Kranzl A; Penzkofer S; Ganger R; Radler C; Haeusler G; Raimann A
Front Endocrinol (Lausanne); 2022; 13():866170. PubMed ID: 35399930
[TBL] [Abstract][Full Text] [Related]
15. Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy.
Brener R; Zeitlin L; Lebenthal Y; Brener A
Front Endocrinol (Lausanne); 2022; 13():947814. PubMed ID: 36051396
[TBL] [Abstract][Full Text] [Related]
16. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
Ward LM; Högler W; Glorieux FH; Portale AA; Whyte MP; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Sochett E; Muroya K; Tanaka H; Pitukcheewanont P; Gottesman GS; Biggin A; Perwad F; Chen A; Lawrence Merritt Ii J; Imel EA
JBMR Plus; 2024 Jan; 8(1):ziad001. PubMed ID: 38690124
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
18. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
[TBL] [Abstract][Full Text] [Related]
19. Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study.
Levy-Shraga Y; Levi S; Regev R; Gal S; Brener A; Lebenthal Y; Gillis D; Strich D; Zung A; Cleper R; Borovitz Y; Bello R; Tenenbaum A; Zadik Z; Davidovits M; Zeitlin L; Tiosano D
Eur J Pediatr; 2023 Nov; 182(11):5191-5202. PubMed ID: 37707589
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
